Nanjing Hicin Pharmaceutical Co Ltd

SHE:300584 China Drug Manufacturers - Specialty & Generic
Market Cap
$672.02 Million
CN¥4.93 Billion CNY
Market Cap Rank
#13233 Global
#3337 in China
Share Price
CN¥41.09
Change (1 day)
+3.32%
52-Week Range
CN¥16.41 - CN¥77.88
All Time High
CN¥83.16
About

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for … Read more

Nanjing Hicin Pharmaceutical Co Ltd (300584) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: -0.007x

Based on the latest financial reports, Nanjing Hicin Pharmaceutical Co Ltd (300584) has a cash flow conversion efficiency ratio of -0.007x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-7.15 Million) by net assets (CN¥1.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Nanjing Hicin Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Nanjing Hicin Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Nanjing Hicin Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nanjing Hicin Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Nanjing Hicin Pharmaceutical Co Ltd (2012–2024)

The table below shows the annual cash flow conversion efficiency of Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥1.04 Billion CN¥59.96 Million 0.058x +138.31%
2023-12-31 CN¥987.50 Million CN¥23.93 Million 0.024x +495.88%
2022-12-31 CN¥950.57 Million CN¥-5.82 Million -0.006x -109.69%
2021-12-31 CN¥948.48 Million CN¥59.94 Million 0.063x -41.53%
2020-12-31 CN¥678.97 Million CN¥73.39 Million 0.108x -27.33%
2019-12-31 CN¥653.98 Million CN¥97.28 Million 0.149x +11.91%
2018-12-31 CN¥580.93 Million CN¥77.21 Million 0.133x +47.79%
2017-12-31 CN¥517.68 Million CN¥46.56 Million 0.090x -34.20%
2016-12-31 CN¥276.11 Million CN¥37.74 Million 0.137x -40.39%
2015-12-31 CN¥235.08 Million CN¥53.90 Million 0.229x +88.91%
2014-12-31 CN¥200.15 Million CN¥24.29 Million 0.121x -55.41%
2013-12-31 CN¥165.93 Million CN¥45.16 Million 0.272x -6.87%
2012-12-31 CN¥132.65 Million CN¥38.77 Million 0.292x --